We address global challenges such as: Dr Mahfuz Kamal has been awarded an Enterprise Fellowship by the Royal Academy of Engineering to support him as CEO of University spin-out company RecoVolt. The ...

As part of its ongoing commitment to sustainability, Concordia recently released findings from its Voluntary University Review (VUR), an institutional self-assessment that began in 2021. The resulting ...

UB hereby grants to you a limited, revocable, non-exclusive, non-transferable, non-sub-licensable use of our logo files for university-approved use only. Use by third parties is granted only for ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition ...

Here are some before and after pictures of the company's wordmark and logo. Need a break? Play the USA TODAY Daily Crossword Puzzle. Here's a look at how the new wordmark and logo will appear on ...

although it has a halal logo printed. (Photo: TikTok/@pembinaum) Police also confirmed on Monday that students from the top university had filed a report on Friday, expressing doubts about the ...

Walmart is refreshing its logo for the first time in nearly two decades, highlighting its evolution while also serving as a nod to its past, the big-box retailer announced Monday. The word mark on ...

A new initiative steered by Concordia researchers is challenging the conversation ... The professor in the Department of Design and Computation Arts is also the University Research Chair in ...

Compass Therapeutics (CMPX) announced a corporate and financial update. Top-line Phase 2/3 data readout for CTX-009, now named tovecimig, in patients with biliary tract cancer is on track for end ...

Cingulate (CING) announced that it has completed its final FDA-required study, which is a food effect study, for CTx-1301 for the treatment of Attention Deficit Hyperactivity Disorder, ADHD.